Efficiencies of platform clinical trials: A vision of the future

Clinical Trials

Volumn 13, Issue 3, 2016, Pages 358-366

  Saville, Benjamin R ^a,b   Berry, Scott M ^a,c  

^a BERRY CONSULTANTS   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

adaptive; Bayesian; clinical trial design; master protocol; multi arm; Platform trial

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; PATIENT; PERSONALIZED MEDICINE; PLATFORM CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; SAMPLE SIZE; SIMULATION; STUDY DESIGN; TREATMENT FAILURE; ADAPTIVE CLINICAL TRIAL (TOPIC); BAYES THEOREM; COMPUTER SIMULATION; METHODOLOGY; TREATMENT OUTCOME;

ADAPTIVE CLINICAL TRIALS AS TOPIC; BAYES THEOREM; COMPUTER SIMULATION; HUMANS; MEDICAL FUTILITY; RESEARCH DESIGN;

EID: 84966533874     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774515626362     Document Type: Article

References (21)

1. MRC Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 769-783.
2. Scannell JW, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012; 11: 191-200.
3. Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol 2015; 32 (1): 40-51.
4. Woodcock J, Woosley R., The FDA critical path initiative and its influence on new drug development. Annu Rev Med 2008; 59: 1-12.
5. Herper M., The cost of creating a new drug now $5 billion, pushing big pharma to change., http://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine (2015,. accessed 16 April 2015).
6. Berry SM, Broglio KR, Groshen S, et al. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials. Clin Trials 2013; 10: 720-734.
7. Berry SM, Connor JT, Lewis RJ., The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015; 313: 1619-1620.
8. Berry DA., The Brave New World of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol 2015; 9 (5): 951-959.
9. Angus DC., Fusing randomized trials with big data: the key to self-learning health care systems? JAMA 2015; 314 (8): 767-768.
10. Esserman LJ, Woodcock J., Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 2011; 306 (23): 2608-2609.
11. Zhou X, Liu S, Kim ES, et al. Bayesian adaptive design for targeted therapy development in lung cancer-a step toward personalized medicine. Clin Trials 2008; 5 (3): 181-193.
12. Steuer CE, Papadimitrakopoulou V, Herbst RS, et al. Innovative clinical trials: the LUNG-MAP study. Clin Pharmacol Ther 2015; 97: 488-491.
13. European Society of Intensive Care Medicine. PREPARE-Platform foR European Preparedness Against (Re) emerging Epidemics., http://www.esicm.org/research/prepare (2015,. accessed 16 April 2015).
14. European Prevention of Alzheimer's Dementia Consortium. 35 partners from industry and academia to join European research initiative for the prevention of Alzheimer's dementia., http://www.mrc-bsu.cam.ac.uk/wp-content/uploads/EPAD-master-press-release-FINAL-1.pdf (2015,. accessed 16 April 2015).
15. President President's Council of Advisors on Science and Technology. Report to the President on Combating Antibiotic Resistance., https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast-carb-report-sept2014.pdf (2014,. accessed 29 April 2015).
16. Korn EL, Freidlin B., Commentary on Hey and Kimmelman. Clin Trials 2015; 12 (2): 122-124.
17. Hey SP, Kimmelman J., Are outcome-adaptive allocation trials ethical? Clin Trials 2015; 12 (2): 102-106.
18. Berry DA., Commentary on Hey and Kimmelman. Clin Trials 2015; 12 (2): 107-109.
19. Lee JJ., Commentary on Hey and Kimmelman. Clin Trials 2015; 12 (2): 110-112.
20. Saville BR, Connor JT, Ayers GD, et al. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. Clin Trials 2014; 11 (4): 485-493.
21. Berry SM, Carlin BP, Lee JJ, et al. Bayesian adaptive methods for clinical trials. Boca Raton, FL: Taylor & Francis Group, 2011.